Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 228.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,286 shares of the company's stock after acquiring an additional 32,202 shares during the quarter. Edgestream Partners L.P.'s holdings in Moderna were worth $3,093,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. International Assets Investment Management LLC increased its stake in Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company's stock valued at $21,353,000 after purchasing an additional 316,552 shares in the last quarter. State of Michigan Retirement System grew its holdings in shares of Moderna by 201.9% during the second quarter. State of Michigan Retirement System now owns 274,248 shares of the company's stock valued at $32,567,000 after buying an additional 183,407 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock valued at $205,431,000 after acquiring an additional 178,939 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company's stock worth $107,885,000 after acquiring an additional 167,596 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Moderna by 30.5% during the 3rd quarter. Citigroup Inc. now owns 591,910 shares of the company's stock worth $39,557,000 after acquiring an additional 138,378 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 2,856 shares of company stock worth $149,374. Corporate insiders own 15.70% of the company's stock.

Moderna Price Performance

Shares of NASDAQ:MRNA traded up $1.20 during midday trading on Monday, reaching $44.26. 6,826,035 shares of the company's stock traded hands, compared to its average volume of 4,900,981. The company has a market cap of $17.03 billion, a P/E ratio of -7.60 and a beta of 1.69. The company has a fifty day simple moving average of $51.98 and a two-hundred day simple moving average of $90.21. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the business earned ($1.39) earnings per share. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. TD Cowen cut their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a report on Friday, September 13th. HSBC upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target on the stock in a report on Monday, November 18th. Piper Sandler restated an "overweight" rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. The Goldman Sachs Group cut their price objective on shares of Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a report on Tuesday, November 26th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $83.33.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.